Promoter Hypermethylation of the ATM Gene as a Novel Biomarker for Breast Cancer
- PMID: 29172272
- PMCID: PMC5773784
- DOI: 10.22034/APJCP.2017.18.11.3003
Promoter Hypermethylation of the ATM Gene as a Novel Biomarker for Breast Cancer
Abstract
Background: Breast cancer may be induced by activation of protooncogenes to oncogenes and in many cases inactivation of tumor suppressor genes. Ataxia telangiectasia mutated (ATM) is an important tumor suppressor gene which plays central roles in the maintenance of genomic integrity by activating cell cycle checkpoints and promoting repair of double-strand breaks of DNA. In breast cancer, decrease ATM expression correlates with a poor outcome; however, the molecular mechanisms underlying downregulation are still unclear. Promoter hypermethylation may contribute in downregulation. Hence the present investigation was designed to evaluate promoter methylation and expression of the ATM gene in breast cancer cases, and to determine links with clinical and demographic manifestations, in a South Indian population. Methods: Tumor biopsy samples were collected from 50 pathologically confirmed sporadic breast cancer cases. DNA was isolated from tumor and adjacent non-tumorous regions, and sodium bisulfite conversion and methylation-specific PCR were performed using MS-PCR primers for the ATM promoter region. In addition, ATM mRNA expression was also analyzed for all samples using real-time PCR. Results: Fifty eight percent (58%) of cancer tissue samples showed promoter hypermethylation for the ATM gene, in contrast to only 4.44% of normal tissues (p= 0.0001). Furthermore, ATM promoter methylation was positively associated with age (p = 0.01), tumor size (p=0.045) and advanced stage of disease i.e. stages III and IV (p =0.019). An association between promoter hypermethylation and lower expression of ATM mRNA was also found (p=0.035). Conclusion: We report for the first time that promoter hypermethylation of ATM gene may be useful as a potential new biomarker for breast cancer, especially in the relatively young patients.
Keywords: Breast cancer; epigenetics; MS-PCR; promoter hypermethylation; ATM; mRNA expression; DSB.
Creative Commons Attribution License
Figures
Similar articles
-
Promoter Hypermethylation of the BRCA1 Gene as a Novel Biomarker for Prostate Cancer.Cureus. 2024 Aug 8;16(8):e66467. doi: 10.7759/cureus.66467. eCollection 2024 Aug. Cureus. 2024. PMID: 39246954 Free PMC article.
-
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2395-2401. doi: 10.31557/APJCP.2020.21.8.2395. Asian Pac J Cancer Prev. 2020. PMID: 32856871 Free PMC article.
-
Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma.Medicine (Baltimore). 2020 Jan;99(4):e18823. doi: 10.1097/MD.0000000000018823. Medicine (Baltimore). 2020. PMID: 31977876 Free PMC article.
-
Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory.Mol Neurobiol. 2015 Aug;52(1):293-302. doi: 10.1007/s12035-014-8864-9. Epub 2014 Aug 27. Mol Neurobiol. 2015. PMID: 25159481
-
The ATM gene is a target for epigenetic silencing in locally advanced breast cancer.Oncogene. 2004 Dec 16;23(58):9432-7. doi: 10.1038/sj.onc.1208092. Oncogene. 2004. PMID: 15516988
Cited by
-
Modulation of DNA damage response by targeting ATM kinase using newly synthesized di-phenoxy acetamide (DPA) analogs to induce anti-neoplasia.Pharmacol Rep. 2021 Oct;73(5):1344-1360. doi: 10.1007/s43440-021-00292-6. Epub 2021 Jun 9. Pharmacol Rep. 2021. PMID: 34109572
-
Protein-altering germline mutations implicate novel genes related to lung cancer development.Nat Commun. 2020 May 11;11(1):2220. doi: 10.1038/s41467-020-15905-6. Nat Commun. 2020. PMID: 32393777 Free PMC article.
-
Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy.Front Pharmacol. 2022 Jun 1;13:908882. doi: 10.3389/fphar.2022.908882. eCollection 2022. Front Pharmacol. 2022. PMID: 35721189 Free PMC article. Review.
-
SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database.Cancer Med. 2019 May;8(5):2303-2312. doi: 10.1002/cam4.2065. Epub 2019 Mar 18. Cancer Med. 2019. PMID: 30883028 Free PMC article.
-
Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals.Int J Mol Sci. 2018 Mar 19;19(3):900. doi: 10.3390/ijms19030900. Int J Mol Sci. 2018. PMID: 29562656 Free PMC article.
References
-
- Ai L, Vo QN, Zuo C, et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev. 2004;13:150–6. - PubMed
-
- Allinen M, Peri L, Kujala S, et al. Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer. 2002;34:384–9. - PubMed
-
- Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1997;72:141–96. - PubMed
-
- Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous